New research suggests that patients who come off new GLP-1 drugs like semaglutide or tirzepatide may regain reduced body mass at a significantly accelerated pace than those who end conventional diet and exercise regimens.
Findings released in a leading health publication shows that while overweight individuals often shed about a fifth of their total mass while on the medication, the mass comes back at an average rate of 0.8 kg per month after stopping.
"Users purchasing such drugs need to be cognizant of the potential of fast weight regain when the therapy concludes," stated lead investigator Dr. Susan Jebb.
Such speed of regain means a return to original weight within about a year and a half.
Comparing Therapies
The study, which reviewed 37 of studies involving thousands of participants, contrasted the results of these new drugs with other pills.
Researchers point out that individuals who lose weight through dieting typically see a more gradual creep back—around 100 grams monthly—once they finish.
Understanding the Rapid Rebound
Experts believe the way of the drugs explains the accelerated rebound.
The injections copy a body's own chemical called GLP-1, which moderates feelings of fullness.
"Long-term administration of GLP-1 levels several times higher than the body's typical production could lead to the system to generate a reduced amount of its own natural hormone, and could reduce sensitivity to its actions," noted Dr. Adam Collins, a dietetics expert.
"Withdrawal of this medication leads to appetite is unsuppressed, making binge eating a significant risk."
An Ongoing Issue?
The NHS suggest the injections for individuals with weight-linked medical conditions, accompanied by recommended lifestyle changes.
Professionals argue that, due to the likelihood of weight regain, the treatment might need to be ongoing.
This opinion is supported by drug manufacturers, who say that the results "underscore the long-term character of excess weight," comparing it to managing conditions like diabetes.
User Experiences
Individuals who have discontinued the medication describe a sudden resurgence of appetite.
"It felt as if a trigger activating and you're instantly ravenous," recalled one woman.
This difficulty is worsened if patients have not developed permanent dietary or behavioural changes during treatment.
Significant Use
Survey data suggest that millions of people in the UK have tried these injections in the last 12 months, with desire remaining high.
- Adoption is more common among females than men.
- The middle-aged age group shows the highest usage rates.
- A large proportion access the drugs through private healthcare rather than public health services.
Finally, experts emphasize that while these medications are powerful agents for shedding pounds, they are not a permanent fix and long-term success likely depends on integrated lifestyle support.
